Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Host Fourth Quarter and Full Year 2013 Financial Results Conference Call and Webcast on Monday, March 3 at 8:00 a.m. ET

SAN RAFAEL, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a...
January 21, 2014 07:35 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Agreement With Repligen for Pre-clinical Compounds

SAN RAFAEL, Calif., Jan. 21, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has entered into an agreement to purchase Repligen Corporation's histone...
January 14, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Doses First Patient in Phase 2 Trial With BMN 111 for the Treatment of Children With Achondroplasia

SAN RAFAEL, Calif., Jan. 14, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first child in the Phase 2 trial with BMN 111, an analog of...
January 13, 2014 08:05 ET | Source: BioMarin Pharmaceutical Inc.

American College of Medical Genetics and Genomics Practice Guidelines Support Lifelong Therapy to Manage Phenylketonuria (PKU)

SAN RAFAEL, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that new practice guidelines issued by the American College of Medical Genetics and...
January 13, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Selection of Factor VIII Gene Therapy Drug Development Candidate BMN 270 for the Treatment of Hemophilia A

SAN RAFAEL, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has selected an AAV-factor VIII vector, BMN 270, to develop for the treatment...
January 07, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

Jean-Jacques Bienaime, CEO of BioMarin, to Present at the 32nd Annual J.P. Morgan Healthcare Conference

SAN RAFAEL, Calif., Jan. 7, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer at BioMarin, will present a...
November 26, 2013 05:10 ET | Source: BioMarin Pharmaceutical Inc.

Dan Spiegelman, CFO of BioMarin, to Present at the Deutsche Bank 2013 BioFest Conference in Boston

SAN RAFAEL, Calif., Nov. 26, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer at BioMarin,...
November 19, 2013 17:02 ET | Source: BioMarin Pharmaceutical Inc.

FDA Advisory Committee Recommends Approval for BioMarin's Vimizim(TM) for the Treatment of Patients With Morquio A Syndrome

SAN RAFAEL, Calif., Nov. 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food...
November 19, 2013 07:10 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Stock Trading Halted Today

SAN RAFAEL, Calif., Nov. 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that NASDAQ has halted trading of the company's stock. The U.S. Food and Drug...
November 15, 2013 09:15 ET | Source: BioMarin Pharmaceutical Inc.

FDA Posts Briefing Documents for Advisory Committee Meeting Reviewing Vimizim(TM) for the Treatment of Morquio A Syndrome

SAN RAFAEL, Calif., Nov. 15, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the U.S. Food and Drug Administration (FDA) posted briefing materials for the November...